MDMA Research Insights
Rick discusses the complexities of conducting double-blind studies with MDMA, revealing the challenges of maintaining blinding while assessing therapeutic effectiveness. He highlights the FDA's acceptance of using inactive placebo alongside full-dose MDMA therapy, emphasizing the necessity for unbiased evaluation through trained independent raters. The conversation sheds light on the evolving landscape of psychedelic research and its implications for therapy.In this clip
From this podcast
The Joe Rogan Experience
Joe Rogan Experience #1661 - Rick Doblin
Related Questions